pyrithione has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 2 studies
pyrithione: split from cephalosporin molecule; some metal complexes of this have fumarate reductase inhibitory activity and may be useful against trypanosomes; RN given refers to parent cpd; structure
pyrithione : A pyridinethione that is pyridine-2(1H)-thione in which the hydrogen attached to the nitrogen is replaced by a hydroxy group. It is a Zn(2+) ionophore; the zinc salt is used as an antifungal and antibacterial agent.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muthyala, R | 1 |
| Shin, WS | 1 |
| Xie, J | 1 |
| Sham, YY | 1 |
| Lan, X | 1 |
| Zhao, C | 1 |
| Chen, X | 1 |
| Zhang, P | 1 |
| Zang, D | 1 |
| Wu, J | 1 |
| Chen, J | 1 |
| Long, H | 1 |
| Yang, L | 1 |
| Huang, H | 1 |
| Carter, BZ | 1 |
| Wang, X | 1 |
| Shi, X | 1 |
| Liu, J | 1 |
2 other studies available for pyrithione and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crystallography, X-Ray; Dose-Response | 2015 |
Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
Topics: Apoptosis; Caspases; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Heterografts; Humans; Imat | 2016 |